Allergan Plc's total net revenue for the third quarter of fiscal 2019 landed at $4.05 billion, improving by 3.6% from the same period a year ago, the company announced on Tuesday.
The company's operating loss was $597 million, representing a 331.7% plunge from the third trimester of 2018. Diluted loss per share increased year-on-year from $0.11 to $2.40 recorded in the third three-month period.
Chairman and CEO of the pharmaceutical company, Brent Saunders, said: "The third quarter 2019 results demonstrate our commitment to continued strong operational performance. The core business has grown and has been bolstered by significant pipeline progress, with three new molecular entities currently under regulatory review."